Clinical Trials for Uterine Cancer

A Phase 2A, Prospective, Open Label, Single Institution Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult women with recurrent/metastatic cervical cancer (squamous, adeno, or adenosquamous), ECOG 0–1, up to two prior systemic lines allowed, including prior PD-1/PD-L1 and antiangiogenic therapy, receive pembrolizumab (PD-1 inhibitor) plus lenvatinib (VEGFR/FGFR/PDGFR/RET/KIT multikinase antiangiogenic) until progression or 2 years, with an option for retreatment. Excludes uncontrolled CNS disease and conditions that raise antiangiogenic risk (e.g., significant cardiovascular disease, proteinuria, GI fistula).

ClinicalTrials.gov ID: NCT06266338

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum‑resistant high‑grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer (1–3 prior lines; prior bevacizumab allowed), ECOG 0–1, measurable disease. Single‑arm regimen adds intermittent relacorilant (selective glucocorticoid receptor modulator to overcome taxane resistance) to nab‑paclitaxel and bevacizumab, given on a 28‑day cycle until progression/toxicity.

ClinicalTrials.gov ID: NCT06906341

Phase II Study of ELacestrant in Combination With Abemaciclib or Elacestrant Alone In p53 Wild Type, Estrogen Receptor-positive Advanced or recurrenT Endometrial Cancer (ELITE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent ER-positive, p53 wild-type endometrial cancer after prior platinum and PD-1 inhibitor therapy (no dMMR/POLE, limited prior lines) are randomized to elacestrant, an oral SERD, alone or combined with abemaciclib, a CDK4/6 inhibitor. Suitable for ECOG 0–1 patients without prior CDK4/6/SERD exposure; stable treated CNS metastases allowed.

ClinicalTrials.gov ID: NCT07209449

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Eligible patients are adults with advanced (stage III–IVA measurable, IVB ± measurable) or recurrent endometrial carcinoma that is mismatch repair–proficient and TP53-aberrant (p53 IHC aberrant or TP53-mutated), ECOG 0–2, with no prior PD-(L)1/CTLA-4 or anti-VEGF therapy and no prior chemo for endometrial cancer except adjuvant completed ≥12 months prior. Patients are randomized to first-line carboplatin/paclitaxel plus pembrolizumab (anti–PD-1) vs carboplatin/paclitaxel plus bevacizumab (anti–VEGF-A) vs carboplatin/paclitaxel plus pembrolizumab plus bevacizumab, followed by maintenance with the assigned biologic(s).

ClinicalTrials.gov ID: NCT07198074

A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adults with locally advanced or metastatic, unresectable uterine sarcoma subtypes with strong ER expression (≥75% tumor cells), measurable disease, and ECOG 0–2, allowing prior chemotherapy/radiation. All patients receive once-daily oral elacestrant, a selective estrogen receptor degrader (SERD), in 28-day cycles until progression or discontinuation.

ClinicalTrials.gov ID: NCT07467772

Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable, recurrent mismatch repair–proficient endometrial carcinoma, including carcinosarcoma, progressing after first-line platinum-doublet chemotherapy plus immunotherapy receive pembrolizumab (anti–PD-1) combined with lenvatinib (oral VEGFR1–3–targeting multikinase inhibitor).

ClinicalTrials.gov ID: NCT07594015

Open-Label Phase II Trial of Enfortumab Vedotin in Recurrent or Persistent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult women with measurable, nectin-4–positive recurrent or progressive endometrioid or serous endometrial carcinoma after hysterectomy, platinum chemotherapy, and immunotherapy when eligible (≤3 prior lines; ECOG 0–1) receive enfortumab vedotin IV on days 1, 8, and 15 of each 28-day cycle. Enfortumab vedotin is a nectin-4–directed antibody-drug conjugate that delivers the microtubule-disrupting payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT07139977

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551